XML 50 R41.htm IDEA: XBRL DOCUMENT v3.22.1
SCHEDULE OF INVESTMENT (Details)
3 Months Ended
Mar. 31, 2022
USD ($)
Melt Pharmaceuticals, Inc. [Member]  
Net Investment Income [Line Items]  
Cost basis $ 19,310,000
Share of Equity Method Losses (11,063,000)
Paid in Kind Interest 1,021,000
In Substance Capital Contributions (1,021,000)
Net carrying value 8,247,000
Common Stock [Member] | Melt Pharmaceuticals, Inc. [Member]  
Net Investment Income [Line Items]  
Cost basis 5,810,000
Share of Equity Method Losses (5,810,000)
Paid in Kind Interest
Common Stock [Member] | Surface Ophthalmics, Inc. [Member]  
Net Investment Income [Line Items]  
Cost basis 5,320,000
Share of Equity Method Losses (5,320,000)
Net carrying value
Loan [Member] | Melt Pharmaceuticals, Inc. [Member]  
Net Investment Income [Line Items]  
Cost basis 13,500,000
Share of Equity Method Losses (5,253,000)
Paid in Kind Interest 1,021,000
In Substance Capital Contributions (1,021,000)
Net carrying value $ 8,247,000